Q2 2026 Stoke Therapeutics Inc Earnings Call Transcript
Key Points
- Stoke Therapeutics Inc (STOK) completed enrollment of 162 patients in the Phase 3 EMPEROR study in just 10 months, with no treatment discontinuations to date, indicating strong patient and physician interest and a well-tolerated profile.
- The company has a robust financial position with a pro forma cash balance of approximately $420 million, providing a runway through a potential US launch in early 2028.
- Long-term data from the Phase 1/2 and open-label extension (OLE) studies show durable seizure reduction and statistically significant improvements in cognition and behavior (Vineland-3 scores) over four years, with no new safety findings.
- Stoke Therapeutics Inc (STOK) is advancing its pipeline, including STK-002 for ADOA, which has completed dosing of the first cohort and is progressing to higher doses, with early results expected in the first half of 2027.
- The company has a clear regulatory path, with a pre-NDA meeting scheduled for late 2026 and a rolling NDA submission planned to begin in Q1 2027, supported by a broad label expectation and commercial readiness activities.
- Commercial planning is well underway, with a lean infrastructure of ~25 sales reps targeting a concentrated US patient population, and market research indicates that payers and healthcare providers view the OLE data as the most compelling evidence for the drug's value.
- The Phase 3 EMPEROR study is still blinded, and the primary endpoint data (percent change in major motor seizure frequency) will not be available until Q3 2027, leaving significant clinical and regulatory uncertainty.
- The company faces potential delays or challenges in the NDA submission process, as the pre-NDA meeting with the FDA will need to align on the statistical analysis plan, including the hierarchy of secondary endpoints, which could impact the approval timeline.
- Stoke Therapeutics Inc (STOK) has not yet demonstrated efficacy in the Phase 3 trial, and the success of the program relies on replicating the strong OLE data, which may not be achieved in a controlled setting.
- The company's cash runway is dependent on potential milestone payments from Biogen and successful execution of its ATM program, which may not be sufficient if development costs increase or timelines slip.
- The ADOA program is at an early stage, with only three patients dosed in the first cohort, and there is no guarantee that higher doses will be safe or that efficacy will be observed, as the company anticipates potential efficacy only in later cohorts.
- The market opportunity for Dravet syndrome is limited to a relatively small patient population (estimated 16,000 in the US), and the company faces competition from existing symptomatic treatments and potential future therapies, which could impact adoption and pricing.
Hello and welcome to the Stoke Therapeutics second quarter 2026 business and financial update. (Operator Instructions) Please be advised that today's conference is being recorded. It is now my pleasure to introduce CFO Thomas Leggett.
Good evening and welcome to Stoke Therapeutics second quarter 2026 business update conference call. I'm Thomas Leggett, the Chief Financial Officer for Stoke Therapeutics. Joining me on today's call are Ian Smith, our Chief Executive Officer, Dr. Barry Ticho, Chief Medical Officer, and Jason Hoitt, Chief Patient Officer.
As a reminder, today's webcast presentation is available in the Investors section of our website. This webcast is being recorded and will be available for replay later this evening. Before we begin, please note that today's discussion includes forward-looking statements. These forward-looking statements are subject to risks and uncertainties and actual results may differ materially.
Please refer to our filings with the SEC for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
